Category: Federal Forum Posters
Purpose: Renal function is a vital concern when addressing management of Type 2 Diabetes Mellitus (T2DM). Due to the high association between T2DM and kidney disease, education and implementations of lifestyle modification and medication management is crucial in glycemic control and renal protection. In June 2016, the FDA issued a statement to warn clinicians and patients of the increased risk of developing Acute Kidney Injury (AKI) while taking a Sodium-Glucose Co-Transporter-2 Inhibitor (SGLT-2 inhibitor). The primary goal of this study is to evaluate the potential impact of SGLT-2 inhibitors on renal function, including increased AKI risk in Veterans with T2DM.
Methods: This study has approved by the local Institutional Review Board. Medical charts at the Battle Creek VA Medical Center will be reviewed on SGLT-2 inhibitor use in Veterans between 18-89 years of age with active SGLT-2 inhibitor prescription between April 1, 2013 and April 1, 2018. The following data will be collected: patient age, gender, body mass index, race, comprehensive medication list, ICD-9/10 diagnosis codes and laboratory values. The incidence of AKI, change in estimated glucose filtration rate from baseline and discontinuation rates of SGLT-2 inhibitors will be calculated. All data will be recorded without patient identifiers and maintained confidentially.
Results: not applicable
Conclusion: not applicable
Samuel Dwyer– Pharmacy Resident, Battle Creek VA Medical Center, Battle Creek, MI